[Retinal dysfunction in patients treated with vigabatrin]
- PMID: 17687922
[Retinal dysfunction in patients treated with vigabatrin]
Abstract
Purpose: To present the current knowledge of vigabatrin influence on the retinal function and to introduce a case report of toxic retinopathy diagnosed in our laboratory, in patient treated with vigabatrin.
Material and methods: A review study based on other authors', concerning the role of diagnostic tests like: perimetry, flash electroretinography (ERG), multifocal electroretinography (mfERG), electrooculography (EOG) in patients treated with vigabatrin and presentation of toxic retinopathy in drug-resistant epileptic patient treated with vigabatrin.
Results: In vigabatrin treated patients a functional or structural retinal changes may occur, what can be measured by electrophysiological and visual field testing. Irreversible abnormalities of visual field and ERG tests results prove the toxic character of retinopathy in presented vigabatrin treated patient.
Conclusions: ERG tests and visual field assessment should be performed in patients treated with vigabatrin. Initial abnormalities occurrence should be a signal for considering the change of therapy.
Similar articles
-
Symptomatic and asymptomatic visual loss in patients taking vigabatrin.Ophthalmology. 1999 Sep;106(9):1792-8. doi: 10.1016/S0161-6420(99)90345-7. Ophthalmology. 1999. PMID: 10485552
-
Binasal visual field defects are not specific to vigabatrin.Epilepsy Behav. 2009 Nov;16(3):521-6. doi: 10.1016/j.yebeh.2009.09.003. Epub 2009 Oct 7. Epilepsy Behav. 2009. PMID: 19815465
-
Visual field constriction and electrophysiological changes associated with vigabatrin.Doc Ophthalmol. 2002 Mar;104(2):151-70. doi: 10.1023/a:1014644307518. Doc Ophthalmol. 2002. PMID: 11999623
-
Recommendations for visual evaluations of patients treated with vigabatrin.Curr Opin Ophthalmol. 2010 Nov;21(6):442-6. doi: 10.1097/ICU.0b013e32833f0085. Curr Opin Ophthalmol. 2010. PMID: 20811279 Review.
-
Ethambutol neuroretinopathy.Semin Ophthalmol. 2007 Jul-Sep;22(3):141-6. doi: 10.1080/08820530701457134. Semin Ophthalmol. 2007. PMID: 17763233 Review.
Cited by
-
Modulation of the GABAergic pathway for the treatment of fragile X syndrome.Neuropsychiatr Dis Treat. 2014 Sep 16;10:1769-79. doi: 10.2147/NDT.S42919. eCollection 2014. Neuropsychiatr Dis Treat. 2014. PMID: 25258535 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical